biosimilars101

Providing news & information about biosimilars—biologic medicines that are FDA-approved based on similarity to an existing biological. RT ≠ Endorsement.

[biosimilars101 @biosimilars101]

Phase 3 clinical trials have started for the biosimilar drug treating plaque psoriasis, which also intends to treat treat autoimmune diseases such as psoriatic arthritis, Crohn's disease, and ulcerative colitis.

https://t.co/5jwPKxHdti

[biosimilars101 @biosimilars101]

It is more crucial than ever that #misinformation on #biosimilars be addressed by the federal government, especially on issues of effectiveness and efficacy.

https://t.co/9nmDj3MD1I

[biosimilars101 @biosimilars101]

The #biosimilars industry can learn valuable lessons and best practices from generic medicines. Hear in a new @AJMC_Journal podcast on how the U.S. generics industry could be instructive in understanding how biosimilar sales may develop over time.

https://t.co/dfkx1ytJQ4

[Alliance for Patient Access @patientaccess]

ICYMI: AfPA's new paper explores how biosimilars offer more treatment options for people living with cancer. Learn more: https://t.co/WgDRiiS0HI

[biosimilars101 @biosimilars101]

From @FitchRatings: "Regulatory and legislative steps are underway to increase biosimilar uptake, given biosimilars are less expensive and highly similar alternatives to higher cost biologics."
https://t.co/aqjTvSWnKZ

[biosimilars101 @biosimilars101]

A #NEW @ASCPTjournals study: Medicare would have saved $2.19 billion on adalimumab spending between 2016 and 2019 had #biosimilars become available in the years they were approved.

Read more study insights from the @BiosimCenter: https://t.co/qEyfLN1kVu

[biosimilars101 @biosimilars101]

#ICYMI: President Biden outlined his administration's support for #biosimilars expansion in an Executive Order, directing @HHSGov to increase their support of biosimilars in the U.S. market.

https://t.co/5Idttaqpnz

[NDTV Profit Alpha @NDTVProfitAlpha]

Cipla plans to launch biosimilars in South Africa, Australia and emerging markets in the next one year.
https://t.co/CTStAmCXgT

[biosimilars101 @biosimilars101]

Kevin Dunleavy of @FiercePharma profiles the expansive growth of #biosimilars and cost savings. He speaks to Bernstein analyst Ronny Gal, who adds biosimilars have been a "moderating force on drug prices."

https://t.co/ariouDft9y

[biosimilars101 @biosimilars101]

@AJMC_Journal interviewed Dr. Ivo Abraham on #COVID's impact on #biosimilars.

He concluded: "We realize biosimilars, certainly the ones in the United States, are just as good as the reference products and we don't have to worry about safety."

https://t.co/zxDEQDUHqR

[biosimilars101 @biosimilars101]

#ICYMI: @AccessibleMeds, along with 25+ patient and provider groups, extended support for the #BIOSIMAct in Congress.

This legislation would incentivize physicians to prescribe #biosimilars.

https://t.co/oJtwI70hr4

[AAM @AccessibleMeds]

Read about the health journeys of everyday Americans helped by generic and biosimilar medicines. https://t.co/VFAEYeOJXh #VoicesofAccess #medswithinreach #generics #biosimilars

[biosimilars101 @biosimilars101]

Authors of a recent @BioDrugsJournal op-ed argue there is a double standard for #biosimilars data and review, calling for "efficiency of development and review because such improvements in efficiency can allow more competition in the marketplace."
https://t.co/ul1i6D5Rd0

[biosimilars101 @biosimilars101]

Soon, Europe, Canada, Israel and New Zealand will see a new commercialized #biosimilar on the market.

Teva and Bioeq are partnering for the commercialization of FYB201, a biosimilar to treat macular degeneration.

https://t.co/vzYlkYDjy8

[biosimilars101 @biosimilars101]

#News from the UK: Updated regulatory guidance that reduces unnecessary clinical trials could put the UK ahead of Europe and facilitate a #biosimilars boom.

Read the full analysis on this change from the @PharmaReview: https://t.co/xPndZe8XEH

[STAT @statnews]

Biosimilars: What will it take to deliver on their promise?

https://t.co/4OEiDDvQa4

[biosimilars101 @biosimilars101]

Oncology is expensive, but "biosimilars present an opportunity to reduce Medicare spending without impacting the quality of care provided to patients," writes Keely Macmillan in @AJMC_Journal.

https://t.co/QvlmjiR9VN

[biosimilars101 @biosimilars101]

Within the recent #AffordableCareAct Supreme Court decision was significant news for #biosimilars in the U.S., as the #BPCIA was upheld.

More from @bloomberglaw: https://t.co/8JkxksDfup

[biosimilars101 @biosimilars101]

Jair Hilburn of @ForbesScience writes on the price-reducing potential of #biosimilars: "They are not only less expensive than brand name biologics themselves, they also apply competitive pressure to the brand name drugs."

https://t.co/p1ntzWzTuW

[Christine Simmon @CSimmon_DC]

This new piece from @Sandoz_Global highlights last month's @Reuters event about unlocking the potential of #biosimilars, where I explained how increased adoption of biosimilars in the U.S. would provide massive savings for patients and taxpayers alike.

https://t.co/sTLmsA2wUk